First-in-human phase 1 trial of the safety, tolerability, pharmacokinetics of BY101298: Initial report from dose escalation cohort. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I ...
BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results